RLS Global carries out an issue of shares by way of set-off, totalling approximately SEK 10
The board of directors of RLS Global AB (publ) (the “Company” or “RLS Global”) has today, pursuant to the authorization granted by the annual general meeting on 19 May 2022, resolved on a directed issue of new shares, totalling approximately SEK 10 million (the “Issue”), to one of the Company’s principal shareholders, i.e., Zebra Holding and Investments (Guernsey) Limited (“Zebra”). The subscription price is approximately SEK 2.987 per share. The issue fund has been paid by set-off of the remaining loan, in a total of approximately SEK 10 million in claim that Zebra had against the Company.
Terms for the Issue
Zebra has earlier provided short-term loans to the Company in total of SEK 10,000,000 (the “Loan”).
The board of directors of RLS Global has today, pursuant to the authorization granted by the annual general meeting on 19 May 2022, resolved on the Issue. Through the Issue the number of shares in the Company will increase by 3,347,840 and the share capital will increase by SEK 378,272.441600. The issue funds have been paid by set-off of the Loan.
The total issue found in the Issue amount to SEK 9,999,998.080.
The subscription price for the shares is SEK 2.987 per share. The subscription price has been determined after negotiations at arms’ length between the Company and Zebra, respectively. Overall, the Company's board of directors is of the opinion that the subscription price is market-based, based on the current circumstances.
The reasons for the deviation from the shareholders’ preferential rights is an opportunity to raise capital on favourable terms in order to strengthen the Company’s liquidity and working capital in a time- and cost-effective manner, which has been of material importance for the Company’s management given the severe financial situation of the Company. According to the board of directors, this indicates all in all and with sufficient strength that it is in the shareholders’ interest to carry out an issue of new shares with derivation from the shareholders’ preferential rights.
The Issue entails a dilution effect corresponding to approximately 4.78 percent in relation to the current number of shares in the Company.
RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the below contact person, 23-09-2022 09:00 CET.
TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget.
FOR MORE INFORMATION, PLEASE CONTACT:
Karin Fischer, CEO, RLS Global
E-mail: karin.fischer@rlsglobal.se
Tel: +46 702 48 46 51
Steve Krognes, Chairman of the Board
E-mail: customer@rlsglobal.com
ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products for some of our most common diseases in wound and dental care. RLS has a portfolio of strong brands, including ChloraSolv® and Carisolv®.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS intends to work with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global